Table 2.

Insulin doses (U/kg) for all dulaglutide 1.5 mg patients and all comparator patients by subgroup and individual study at 6 months

	HbA1c		Age		Duration of diabetes
	≤9%	>9%	<65 y	≥65 y	<10 y	≥10 y
AWARD‐4
Dulaglutide 1.5 mg + insulin lispro
Lispro dose	0.9 ± 0.7	1.1 ± 0.6	1.0 ± 0.6	1.0 ± 0.9	1.0 ± 0.6	1.0 ± 0.7
Insulin glargine + insulin lispro
Total daily insulin dose	1.3 ± 0.7	1.6 ± 0.8	1.4 ± 0.8	1.4 ± 0.7	1.5 ± 0.9	1.3 ± 0.7
Glargine dose	0.7 ± 0.4	0.8 ± 0.4	0.7 ± 0.4	0.7 ± 0.3	0.7 ± 0.5	0.7 ± 0.3
Lispro dose	0.7 ± 0.4	0.8 ± 0.5	0.7 ± 0.4	0.7 ± 0.4	0.8 ± 0.5	0.7 ± 0.4
AWARD‐9
Dulaglutide 1.5 mg + insulin glargine
Glargine dose	0.6 ± 0.3	0.7 ± 0.3	0.6 ± 0.3	0.5 ± 0.3	0.6 ± 0.3	0.6 ± 0.3
Placebo + insulin glargine
Glargine dose	0.6 ± 0.3	0.9 ± 0.5	0.7 ± 0.4	0.6 ± 0.3	0.7 ± 0.4	0.7 ± 0.3

Abbreviation: HbA1c, glycated haemoglobin.

Data are presented as mean ± SD. Insulin lispro was administered three times daily.